{{Infobox drug
| drug_name = 
| IUPAC_name = Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide
| image = Umeclidinium bromide.svg
| alt = 
| caption = 

<!--Clinical data -->
| tradename = Incruse Ellipta
| Drugs.com = 
| MedlinePlus = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = Rx-only
| legal_status = Rx-only
| routes_of_administration = Inhalation ([[Dry powder inhaler|DPI]])

<!--Pharmacokinetic data -->
| bioavailability = 
| protein_bound = ~89%<ref name = "PI">{{cite web|title=Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information|url=https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Incruse_Ellipta/pdf/INCRUSE-ELLIPTA-PI-PIL.PDF|publisher=GlaxoSmithKline, Research Triangle Park, NC 27709|accessdate=22 February 2016}}</ref>
| metabolism = [[Liver|Hepatic]] ([[CYP2D6]])
| elimination_half-life = 11 hours
| excretion = [[Feces]] (58%) and [[urine]] (22%)

<!--Identifiers -->
| CAS_number = 869113-09-7
| ATCvet = 
| ATC_prefix = R03
| ATC_suffix = BB07
| ATC_supplemental  = <br/>{{ATC|R03|AL03}} (+[[vilanterol]])
| PubChem = 11519069
| ChEBI = 79040
| DrugBank = 
| ChemSpiderID = 9693857
| synonyms = GSK573719A
| KEGG = D10181
<!--Chemical data -->
| C=29 | H=34 | Br=1 | N=1 | O=2
| molecular_weight  = 508.49 g/mol
| StdInChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1
| StdInChIKey= PEJHHXHHNGORMP-UHFFFAOYSA-M
| smiles = C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-]
}}

'''Umeclidinium bromide''' (trade name '''Incruse Ellipta''', [[GlaxoSmithKline|GSK]])  is a long-acting [[muscarinic antagonist]] approved for the maintenance treatment of [[chronic obstructive pulmonary disease]] (COPD).<ref name = "PI" /> It is also approved for this indication in combination with [[vilanterol]] (as [[umeclidinium bromide/vilanterol]]).<ref>{{cite journal | pmid= 24004659 | year= 2013 | last1= Feldman | first1= GJ | last2= Edin | first2= A | title= The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: Current evidence and future prospects | volume= 7 | issue= 6 | pages= 311â€“9 | doi= 10.1177/1753465813499789 | journal= Therapeutic advances in respiratory disease}}</ref><ref>{{Cite news | title = FDA Approves Umeclidinium and Vilanterol Combo for COPD | url = http://www.medscape.com/viewarticle/817964 | date = December 18, 2013 | publisher = Medscape}}</ref>

==External links==
* [http://www.incruse.com Incruse Ellipta (umeclidinium inhalation powder) Official Site]

==References==
{{reflist}}

{{Drugs for obstructive airway diseases}}
{{Muscarinic acetylcholine receptor modulators}}

[[Category:Bromides]]
[[Category:Drugs acting on the respiratory system]]
[[Category:Muscarinic antagonists]]
[[Category:Quaternary ammonium compounds]]
[[Category:Quinuclidines]]

{{respiratory-system-drug-stub}}